Verrica Pharmaceuticals Inc. (VRCA) stock
VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.20−0.36 (-10.11%)
Close on Nov 16, 2026Market cap $54.97MP/E –Yield –
Verrica Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Verrica Pharmaceuticals's total assets was $36.02M at Jun 30, 2026. For fiscal 2025 it was $47.13M, down 12.9% from the year before. The highest annual figure on record is $91.91M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.13M | -12.9% |
| FY2024 | Dec 31, 2024 | $54.13M | -33.7% |
| FY2023 | Dec 31, 2023 | $81.60M | +82.5% |
| FY2022 | Dec 31, 2022 | $44.72M | -44.2% |
| FY2021 | Dec 31, 2021 | $80.13M | +8.1% |
| FY2020 | Dec 31, 2020 | $74.15M | +8.4% |
| FY2019 | Dec 31, 2019 | $68.42M | -25.6% |
| FY2018 | Dec 31, 2018 | $91.91M | +911.8% |
| FY2017 | Dec 31, 2017 | $9.08M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $36.02M | -7.9% |
| Q1 FY2026 | Mar 31, 2026 | $38.79M | -8.0% |
| Q4 FY2025 | Dec 31, 2025 | $47.13M | -12.9% |
| Q3 FY2025 | Sep 30, 2025 | $40.90M | +24.2% |
| Q2 FY2025 | Jun 30, 2025 | $39.11M | -24.8% |
| Q1 FY2025 | Mar 31, 2025 | $42.18M | -36.4% |
| Q4 FY2024 | Dec 31, 2024 | $54.13M | -33.7% |
| Q3 FY2024 | Sep 30, 2024 | $32.93M | -66.1% |
| Q2 FY2024 | Jun 30, 2024 | $52.01M | -16.4% |
| Q1 FY2024 | Mar 31, 2024 | $66.31M | -3.4% |
| Q4 FY2023 | Dec 31, 2023 | $81.60M | +82.5% |
| Q3 FY2023 | Sep 30, 2023 | $97.15M | +97.7% |
| Q2 FY2023 | Jun 30, 2023 | $62.20M | -1.9% |
| Q1 FY2023 | Mar 31, 2023 | $68.64M | -4.2% |
| Q4 FY2022 | Dec 31, 2022 | $44.72M | -44.2% |
| Q3 FY2022 | Sep 30, 2022 | $49.15M | -44.6% |
| Q2 FY2022 | Jun 30, 2022 | $63.44M | -35.9% |
| Q1 FY2022 | Mar 31, 2022 | $71.62M | -33.8% |
| Q4 FY2021 | Dec 31, 2021 | $80.13M | +8.1% |
| Q3 FY2021 | Sep 30, 2021 | $88.76M | +11.0% |
| Q2 FY2021 | Jun 30, 2021 | $99.03M | +13.5% |
| Q1 FY2021 | Mar 31, 2021 | $108.10M | +14.5% |
| Q4 FY2020 | Dec 31, 2020 | $74.15M | +8.4% |
| Q3 FY2020 | Sep 30, 2020 | $79.94M | +5.1% |
| Q2 FY2020 | Jun 30, 2020 | $87.24M | +7.4% |
| Q1 FY2020 | Mar 31, 2020 | $94.44M | +9.8% |
| Q4 FY2019 | Dec 31, 2019 | $68.42M | -25.6% |
| Q3 FY2019 | Sep 30, 2019 | $76.07M | -23.0% |
| Q2 FY2019 | Jun 30, 2019 | $81.25M | -22.4% |
| Q1 FY2019 | Mar 31, 2019 | $85.98M | +846.6% |
| Q4 FY2018 | Dec 31, 2018 | $91.91M | – |
| Q3 FY2018 | Sep 30, 2018 | $98.81M | – |
| Q2 FY2018 | Jun 30, 2018 | $104.72M | – |
| Q4 FY2017 | Dec 31, 2017 | $9.08M | – |
See a number that looks wrong?